Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

KEY TAKEAWAYS Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...

Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...

Moderna has received Health Canada’s approval for its respiratory syncytial ... which is essential for the virus’ ability to infect host cells. The drug also received US Food and Drug Administration ...

Moderna's mResvia is approved for people age 60 and older. During its first quarter on the market, mResvia generated just $10 ...

Moderna is most well known for its Covid-19 vaccine, which is called Spikevax. The most recent version of Spikevax was approved by the U.S. Food and Drug Administration in August ahead of the fall ...

It was later granted full FDA approval in August 2021 for people ages 16 and older. Pfizer’s and Moderna's vaccine has been updated over time to target currently circulating variants ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...